Key insights
- Baxter International's upcoming earnings report is expected to show declines in revenue and earnings due to leadership changes and operational headwinds. Analysts are closely watching the company's turnaround efforts and potential pressure from hospital capital spending pullbacks. The stock is currently rated as a hold.
Baxter International Inc. is scheduled to report first-quarter earnings Thursday before the market opens, with analysts bracing for sharp declines as the medical-device maker navigates a leadership overhaul and operational headwinds.
Wall Street expects revenue of $2.62 billion, down 0.8% from the prior-year quarter, while earnings are forecast at 31 cents per share, a 43.6% year-over-year decline. The outlook marks a significant sequential retreat from the prior quarter, when Baxter posted earnings of $0.44 per share on $2.97 billion in revenue, underscoring mounting pressure on the $9.26 billion company.
Management has already signaled that the quarter will likely be the most challenging of the year, tempering expectations ahead of the release. EPS estimates have declined 2.82% over the past week, though they’ve remained relatively stable over the past two months. Revenue estimates have been essentially flat in recent weeks.
Analysts rate the stock a hold, with a mean price target of $22.12 implying 23% upside from the current $17.94 share price. Fifteen analysts cover the stock, with three buy ratings, 12 holds and no sells.
What Investors Are Watching
The quarter comes amid substantial leadership changes. CFO Joel Grade stepped down March 16 and will stay at Baxter in an advisory role through April 30, while former EVP Reazur Rasul departed the company effective April 1. BofA Securities analyst Travis Steed noted that the new CEO is "building out his new team" and working to establish "a culture of accountability" after challenging execution over the past two-and-a-half years.
Baxter faces significant challenges, including operational disruptions affecting its product lines. Analysts have flagged that companies like Baxter, which make medical equipment, could feel pressure from potential hospital capital spending pullbacks.
The company has been rolling out new products, including the Dynamo Series smart stretcher, as it attempts to shift toward higher-margin connected devices and software solutions.
In the prior quarter, Baxter beat revenue expectations with $2.97 billion, up 8% year over year, but missed earnings estimates by 18.5%, delivering $0.44 per share against a $0.54 consensus.
The question now is whether CEO Andrew Hider’s turnaround efforts can begin to show traction—or whether operational pressures will continue to weigh on results as the company works through what management has characterized as its toughest stretch of the year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.